Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04356339 · ClinicalTrials.gov registry record

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

A clinical trial, sponsored by Bayer.

Completed
Registry status
100
Enrollment target

NCT04356339 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04356339 has completed, sponsored by Bayer.

COMPLETED
Registry status
100 participants
Enrollment target

Study Summary

In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp. Multiple sclerosis (MS) is a disease in which the covering called "myelin" around the nerves of the central nervous system degenerate. MS is a lifelong disease therefore requiring continuous treatment to delay the disease progression and reduce the rate of relapse (the return of signs and symptoms of). BETASERON is an approved medicine used to reduce the relapse in patients with MS. It is injected into the tissue under the skin using BETACONNECT autoinjector, which automatically captures injection data including injection date, time, speed, and depth and uploads the data into paired myBETAapp. This allows patients to organize and track their progress and share the injection information with their physicians. The medication usage behavior to be collected in this study includes the elements to what extent * taking medication matches the presciber's recommendation (adherence, compliance), * treatment for the prescribed duration (persistence) is continued and * injections were missed. Among MS patients treated with Betaferon using the myBETAapp the study will also collect information on the health-related quality of life , treatment satisfaction and satisfaction with treatment support.

Interventions

  • DRUG Interferon-beta-1b (BETASERON, BAY 86-5046)

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2020-11-24
Est. Completion 2021-11-11

Sponsor

Bayer

591 total trials

What the Registry Record Tells You About NCT04356339

The ClinicalTrials.gov registry entry for NCT04356339 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Interferon-beta-1b (BETASERON, BAY 86-5046) is the first listed.

NCT04356339 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04356339 about?

NCT04356339 is a clinical study titled "US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector". In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp. Multiple sclerosis (MS) is a disease in which the covering called "myelin" around the nerves of the central nervous system degenerate. M...

What is the current status of trial NCT04356339?

This trial is currently completed. The enrollment target is 100 participants. The study started on 2020-11-24. Estimated completion is 2021-11-11.

What interventions are being tested in trial NCT04356339?

The interventions under investigation include: Interferon-beta-1b (BETASERON, BAY 86-5046) (DRUG).

Who is sponsoring clinical trial NCT04356339?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.